ARROWHEAD PHARMACEUTICALS INC
NASDAQ: ARWR (Arrowhead Pharmaceuticals, Inc.)
Last update: yesterday, 8:58PM65.14
-1.09 (-1.65%)
| Previous Close | 66.23 |
| Open | 66.52 |
| Volume | 1,404,190 |
| Avg. Volume (3M) | 2,652,029 |
| Market Cap | 9,121,696,768 |
| Price / Earnings (TTM) | 40.71 |
| Price / Earnings (Forward) | 97.09 |
| Price / Sales | 7.71 |
| Price / Book | 15.04 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Profit Margin | -26.41% |
| Operating Margin (TTM) | 70.24% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -29.60% |
| Total Debt/Equity (MRQ) | 108.23% |
| Current Ratio (MRQ) | 5.15 |
| Operating Cash Flow (TTM) | 61.15 M |
| Levered Free Cash Flow (TTM) | -6.46 M |
| Return on Assets (TTM) | -5.86% |
| Return on Equity (TTM) | -26.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Arrowhead Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.25 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.02% |
| % Held by Institutions | 77.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fred Alger Management, Llc | 31 Dec 2025 | 1,832,997 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Piper Sandler, 68.87%) | Buy |
| Median | 101.00 (55.05%) | |
| Low | 100.00 (HC Wainwright & Co., 53.52%) | Buy |
| Average | 103.67 (59.15%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 66.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Feb 2026 | 100.00 (53.52%) | Buy | 62.92 |
| 21 Jan 2026 | 100.00 (53.52%) | Buy | 67.60 | |
| B. Riley Securities | 22 Jan 2026 | 101.00 (55.05%) | Buy | 69.59 |
| Piper Sandler | 13 Jan 2026 | 110.00 (68.87%) | Buy | 65.55 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results |
| 04 Feb 2026 | Announcement | Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 |
| 27 Jan 2026 | Announcement | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia |
| 20 Jan 2026 | Announcement | Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |